Literature DB >> 1733147

Prevention of secondary transmission of pertussis in households with early use of erythromycin.

M A Sprauer1, S L Cochi, E R Zell, R W Sutter, J R Mullen, S J Englender, P A Patriarca.   

Abstract

To examine the effectiveness of erythromycin therapy and prophylaxis for pertussis, 17 households with one secondary case or more were compared with 20 households without secondary cases following a community-wide pertussis outbreak in Maricopa County, Arizona, in 1988. There were no significant differences between the two household groups in age distribution of members, size, crowding, race, proportion of children aged 7 months to 18 years with three or more diphtheria and tetanus toxoids and pertussis vaccine doses, or in the age distribution, vaccination status, or medical care of patients with primary cases. However, median intervals from onset of illness in primary cases to initiation of erythromycin therapy (for cases) and prophylaxis (for contacts) were 11 and 16 days, respectively, in households without secondary spread, vs 21 and 22 days, respectively, in households with secondary spread. These results provide additional evidence that erythromycin is effective in the medical management of pertussis and should be initiated promptly to minimize secondary spread.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733147     DOI: 10.1001/archpedi.1992.02160140043018

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  14 in total

1.  Pertussis is increasing in unimmunized infants: is a change in policy needed?

Authors:  S Ranganathan; R Tasker; R Booy; P Habibi; S Nadel; J Britto
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

2.  An improved immunofluorescent reagent for rapid, direct detection of Bordetella pertussis.

Authors:  D Martin; P McNicol; R Marchand; P Lebel; M S Peppler; B R Brodeur
Journal:  Can J Infect Dis       Date:  1995-01

Review 3.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

4.  Update of epidemiology, diagnosis, and treatment of pertussis.

Authors:  J E Hoppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

5.  Polymorphism in the pertussis toxin promoter region affecting the DNA-based diagnosis of Bordetella infection.

Authors:  M Nygren; E Reizenstein; M Ronaghi; J Lundeberg
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance.

Authors:  J M Bartkus; B A Juni; K Ehresmann; C A Miller; G N Sanden; P K Cassiday; M Saubolle; B Lee; J Long; A R Harrison; J M Besser
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

7.  Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology.

Authors:  C A Ewanowich; L W Chui; M G Paranchych; M S Peppler; R G Marusyk; W L Albritton
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

8.  Pertussis Infection in a Naturopathic Primary Care Setting: Reflection on a Case.

Authors:  Luciano Garofalo; Joshua Corn; Meghan Sperandeo
Journal:  Perm J       Date:  2020

9.  Sensitivity and specificity of single IgA and IgG antibody concentrations for early diagnosis of pertussis in adults: an evaluation for outbreak management in public health practice.

Authors:  Paul L J M Mertens; Frans S Stals; Ewout W Steyerberg; Jan H Richardus
Journal:  BMC Infect Dis       Date:  2007-06-06       Impact factor: 3.090

10.  Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants.

Authors:  Aaron M Wendelboe; Michael G Hudgens; Charles Poole; Annelies Van Rie
Journal:  Emerg Themes Epidemiol       Date:  2007-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.